Monday, February 10, 9:00 a.m. - 9:55 a.m. | Jade
One model for maximizing biotech value creation is ‘Solution Development’, which calls for a company to develop multiple agents for a single overarching indication, either to identify the best one of many or to develop combinations. The panel will contrast this Solution Development model against the traditional model of developing a single drug for a single indication or multiple drugs but for disparate indications. How will using a Solution Development model impact clinical/regulatory strategy, competitive positioning, financing strategy, and M&A game theory?
- Peter Kolchinsky, PhD, Managing Director, RA Capital Management, LLC
- Christopher Anzalone, PhD, President & CEO, Arrowhead Research Corporation
- Milind S. Deshpande, PhD, President & CEO, Achillion Pharmaceuticals
- Stanley C. Erck, President & CEO, Novavax
- Kurt Graves, Chairman, President & CEO, Intarcia Therapeutics
Christopher Anzalone, PhD
Dr. Anzalone is the President and Chief Executive Officer of Arrowhead Research. He has a wealth of experience in nanotechnology, biotechnology, company-building, and venture capital. Prior to joining Arrowhead, Dr. Anzalone founded and built The Benet Group, a private equity firm focused on creating and building new nanobiotechnology companies from university-generated science. Included in The Benet Group's portfolio are investments in two nanotechnology companies: Nanotope Inc., a tissue regeneration company, and Leonardo Biosystems Inc., a cancer drug delivery company. Prior to Benet, Dr. Anzalone was a partner at the Washington DC-based private equity firm Galway Partners, LLC where he was in charge of sourcing, structuring, and building new business ventures. He was also the founding CEO of NanoInk, Inc., a leading nanolithography company.
Dr. Anzalone holds a Ph.D. and M.A. in Biology from UCLA and a B.A. in Government from Lawrence University.
Milind S. Deshpande, PhD
Dr. Deshpande joined Achillion in September 2001 as Vice President of Chemistry, was named Head of Drug Discovery in April 2002, Senior Vice President of Drug Discovery in December 2002, Senior Vice President and Chief Scientific Officer in December 2004, and Executive Vice President of Research and Chief Scientific Officer in June 2007. He was promoted to President Research and Development in October 2010. In May 2013, Dr. Deshpande was appointed President and Chief Executive Officer of Achillion and joined the Board of Directors.
Prior to joining Achillion, Dr. Deshpande was Associate Director of Lead Discovery and Early Discovery Chemistry at the Pharmaceutical Research Institute at Bristol-Myers Squibb from 1991 to 2001, where he managed the identification of new clinical candidates to treat infectious and neurological diseases. From 1988 to 1991, he held a faculty position at Boston University Medical School. Dr. Deshpande received his Ph.D. in Organic Chemistry from Ohio University, following his undergraduate education in India.
Stanley C. Erck
Mr.Erck was named President and Chief Executive Officer of Novavax in April 2011. He became a Novavax Director in June 2009 and beginning in February 2010, served as its Executive Chairman of the Board. From 2000 to 2008, Mr. Erck was President and Chief Executive Officer of Iomai Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate.
Prior to Iomai, Mr. Erck served as President and Chief Executive Officer of Procept, a publicly traded immunology company; as Vice President, Corporate Development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the Board of Directors of BioCryst Pharmaceuticals, MaxCyte, Inc. and the MdBio Foundation. He received his undergraduate degree from the University of Illinois and his Masters in Business Administration from the University of Chicago Graduate School of Business.
Mr. Graves has been Chairman, President and CEO of Intarcia since April 2012, having previously served solely as Chairman of the company since August 2010 and as Acting CEO since October 2011. He is a global industry leader with more than twenty years of U.S. and global general management experience in top-tier U.S. and European based pharmaceutical and biotech companies. He has successfully built and managed several of the largest multi-billion dollar franchises in the industry and developed and launched more than 10 blockbuster brands in a broad range of general medicine, specialty and orphan disease areas. In addition to driving dynamic top and bottom-line growth in large global pharmaceutical companies, Mr. Graves also played a key leadership role in building two highly successful early stage companies; at Astra Merck Pharmaceuticals and Vertex Pharmaceuticals. Prior to joining Intarcia, Mr. Graves was EVP, Chief Commercial Officer and Head of Corporate and Strategic Development at Vertex Pharmaceuticals from 2007 through the end of 2009. Prior to his tenure at Vertex, he spent nearly ten years at Novartis Pharmaceuticals, most recently as Global Head of the General Medicines Business & Chief Marketing Officer for the Pharmaceuticals division. Prior to Novartis, Mr. Graves held several commercial and general management positions at Merck and Astra Merck/Astra Pharmaceuticals where he spent most of his time leading the GI Business Unit responsible for Prilosec and Nexium. In addition to Intarcia, Mr. Graves serves as Chairman of the Board of Radius therapeutics and as a Director at Springleaf Therapeutics and Pulmatrix Pharmaceuticals. Mr. Graves earned his B.S. in Biology from Hillsdale College and has attended numerous executive leadership programs at Harvard, Wharton School of Management and University of Michigan.
Peter Kolchinsky, PhD
Peter Kolchinsky, PhD, is a founding Partner and Portfolio Manager at RA Capital. Mr. Kolchinsky is active in both public and private investments across drugs, medical devices, diagnostics, and life-science tools. He authored the e-book “the Entrepreneur’s Guide to a Biotech Startup”, serves on the board of the American Fertility Association, and is a board member of several private healthcare companies. In the past, he has served on the Board of Global Science and Technology for the National Academies of Sciences. Mr. Kolchinsky received a Ph.D. in Virology from Harvard University. His doctoral work involved studies of the mechanism by which HIV infects cells. He received a Bachelors degree from Cornell University.